Artiva Biotherapeutics awarded CEO Aslan Fred 110,000 shares at $0 on 2026-09-15, while also granting 315,000 derivative securities. The resulting holdings give investors a clear view of Fred’s post-award position: 1,604,765 shares and 315,000 derivative securities.
Key Highlights
- Aslan Fred’s resulting Artiva Biotherapeutics share holding was 1,604,765.
- The executive received 315,000 derivative securities on 15 September 2026.
- The share award represented about 6.9% of Fred’s resulting share holding.
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) awarded Chief Executive Officer Aslan Fred 110,000 shares at $0 on 15 September 2026. The transaction was recorded under code A. The award was recorded for Artiva Biotherapeutics shares.
Share Award and Resulting Position
Fred’s share holding following the transaction stood at 1,604,765. The 110,000-share award represented about 6.9% of that resulting holding. The transaction date was 15 September 2026. Artiva Biotherapeutics identified Fred as its Chief Executive Officer in the transaction record.
Derivative Securities Awarded
The same transaction record showed an award of 315,000 derivative securities to Fred. His resulting derivative-securities holding was 315,000. The derivative-securities award represented about 100.0% of his resulting derivative-securities holding. Code A applied to that award as well.
FAQs
Q: How many Artiva Biotherapeutics shares did Aslan Fred receive?
A: Artiva Biotherapeutics awarded CEO Aslan Fred 110,000 shares at $0. The award was recorded on 15 September 2026 under transaction code A.
Q: How many derivative securities were awarded to Aslan Fred?
A: Artiva Biotherapeutics awarded Fred 315,000 derivative securities on September 15, 2026, under SEC transaction code A. following the award, his resulting derivative-securities holding was 315,000.
Q: What was the transaction code for Aslan Fred’s Artiva award?
A: The transaction used code A for Aslan Fred’s Artiva Biotherapeutics awards. Both the 110,000-share award and the 315,000 derivative-securities award were recorded on 15 September 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.